Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AnaptysBio, Inc. (ANAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on immunology therapeutics, AnaptysBio uses these filings to report material events related to its clinical programs, collaborations, capital allocation decisions and strategic plans.
Recent Form 8-K filings describe several categories of information. Some filings report results of operations and financial condition, where AnaptysBio furnishes press releases detailing quarterly financial results and business updates. Others fall under Regulation FD disclosure, such as filings that provide updated corporate investor presentations or slide decks used in conference calls discussing programs like ANB033 or the company’s broader pipeline.
Additional 8-Ks highlight other events, including board authorization of amendments to the company’s stock repurchase plan and the board’s approval of plans to explore separating AnaptysBio’s business into two independent, publicly traded companies by the end of 2026. Filings also cover the company’s Verified Complaint in Delaware Chancery Court against Tesaro and GSK concerning the Collaboration and Exclusive License Agreement for Jemperli, as well as references to Tesaro and GSK’s complaint against AnaptysBio.
For investors analyzing ANAB, these filings help clarify how AnaptysBio reports litigation developments, collaboration terms, royalty monetization arrangements, and major strategic decisions. On Stock Titan, SEC documents are paired with AI-powered summaries that explain the main points of each filing in plain language, highlight notable items such as litigation updates or changes to repurchase plans, and make it easier to scan multiple 8-Ks and other forms without reading every line of legal text.
AnaptysBio Chief Medical Officer Paul F. Lizzul reported routine equity activity involving vested RSUs and a related share sale. On January 3, 2026, 10,555 restricted stock units were converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held common stock to 37,522 shares. Each RSU represents the right to receive 1 share of common stock for no cash consideration.
On January 5, 2026, he sold 4,219 shares of common stock at $43.26 per share, leaving him with 33,303 directly owned shares. According to the disclosure, this sale was executed solely to cover tax withholding obligations from the RSU vesting through a "sell to cover" transaction and is described as not a discretionary transaction. The RSUs vest 25% annually starting January 3, 2025, subject to his continued service.
AnaptysBio insider files to sell common stock under Rule 144. A holder plans to sell 4,219 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/05/2026 on NASDAQ, with an aggregate market value of $189,644.05. The filing notes 28,023,368 shares of the issuer’s common stock outstanding, providing a baseline for the company’s share count. The shares to be sold were acquired as restricted stock units from the issuer on 01/05/2026, with payment listed as cash on the same date.
The form also reports that Paul F. Lizzul sold 1,500 common shares on 12/22/2025 for gross proceeds of $75,000 during the prior three months. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
AnaptysBio chief legal officer Eric Loumeau reported RSU vesting and a related share sale. On January 3, 2026, 7,287 restricted stock units converted into an equal number of AnaptysBio common shares at an exercise price of
On January 5, 2026, Loumeau sold 2,983 common shares at
An ANAB insider filed a Rule 144 notice to sell 2,983 shares of common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $134,085.85. The shares come from restricted stock units acquired and paid for in cash on 01/05/2026.
The notice also lists recent activity over the prior three months, where Eric J. Loumeau sold multiple blocks of common stock on various December 2025 dates, with individual transactions ranging up to 10,000 shares and gross proceeds in the hundreds of thousands of dollars. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
AnaptysBio, Inc.'s Chief Medical Officer reported an equity transaction involving company stock. On 12/22/2025, the officer exercised 1,500 employee stock options at an exercise price of $18.50 per share and acquired the same number of common shares. On the same date, the officer sold 1,500 shares of common stock at a price of $50.00 per share. After these transactions, the officer directly owned 26,967 shares of AnaptysBio common stock and held 83,500 stock options from the reported grant.
The filing notes that the sale was made under a Rule 10b5-1 trading plan adopted on April 14, 2025, which is a pre-arranged plan for trading shares. It also states that the reported stock option is fully vested and that the officer holds additional options to purchase up to an aggregate of 394,810 shares of common stock, which vest according to their terms.
AnaptysBio’s chief legal officer reported option exercises and share sales. On December 16–18, 2025, the officer exercised employee stock options to buy common stock at $14.02 and $20.16 per share, then sold portions of the resulting shares in several trades.
Sales were made under a pre-arranged Rule 10b5-1 trading plan, with weighted average sale prices including $44.6756, $45.2369 and $46.00 per share. After these transactions, the officer directly owned 8,947 shares of common stock and held fully vested options covering 53,000 shares, plus additional options to purchase up to 414,810 shares that vest according to their terms.
AnaptysBio, Inc. reported an insider stock transaction by its Chief Financial Officer. On 12/16/2025, the CFO exercised an employee stock option to buy 10,000 shares of common stock at an exercise price of $20.16 per share, increasing directly held shares.
That same day, the CFO sold 9,365 shares at a weighted average price of $44.6152 per share and 6,360 shares at a weighted average price of $45.2062 per share under a pre-arranged Rule 10b5-1 trading plan adopted on April 11, 2025. After these transactions, the CFO directly owned 15,761 and then 9,401 shares of common stock and continued to hold 70,600 vested stock options reported in the table, plus additional options to purchase up to an aggregate of 339,440 shares that vest according to their terms.
AnaptysBio, Inc. reported that its Board of Directors authorized an amendment to its Stock Repurchase Plan, allowing the company to repurchase up to an additional $100.0 million of its outstanding common stock. This expands the capital return program beyond the existing authorization.
As of November 20, 2025, $6.4 million remained available under the current $75.0 million Stock Repurchase Plan. The company has already repurchased 3,443,188 shares of common stock, representing 11.2% of shares outstanding before the start of the plan, signaling a significant reduction in its share count over time.
FAQ
What is the current stock price of Anaptysbio (ANAB)?
What is the market cap of Anaptysbio (ANAB)?
